Avidian Wealth Enterprises LLC Acquires 73 Shares of Stryker Co. (NYSE:SYK)

Avidian Wealth Enterprises LLC grew its holdings in Stryker Co. (NYSE:SYK) by 2.8% during the 4th quarter, Holdings Channel reports. The fund owned 2,680 shares of the medical technology company’s stock after buying an additional 73 shares during the period. Avidian Wealth Enterprises LLC’s holdings in Stryker were worth $965,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in SYK. Dunhill Financial LLC raised its position in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the period. Darwin Wealth Management LLC bought a new position in Stryker in the third quarter worth approximately $36,000. Activest Wealth Management bought a new position in Stryker in the fourth quarter worth approximately $36,000. Crews Bank & Trust bought a new position in Stryker in the fourth quarter worth approximately $39,000. Finally, Hara Capital LLC bought a new position in Stryker in the third quarter worth approximately $42,000. 77.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of NYSE:SYK opened at $385.49 on Thursday. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a market capitalization of $146.96 billion, a P/E ratio of 49.68, a PEG ratio of 2.98 and a beta of 0.96. The firm has a fifty day simple moving average of $377.27 and a two-hundred day simple moving average of $366.01. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the company posted $3.46 earnings per share. On average, analysts expect that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. Stryker’s payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the topic of several recent analyst reports. Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Barclays raised their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday. JPMorgan Chase & Co. raised their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Citigroup raised their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Evercore ISI raised their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.